Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Marisol Miranda, Kellen Cristine Tjioe, Muhannad Sharara, Maloney Mckenzie, Amany R. Keruakous, Locke Johnson Bryan, Anand Jillella, Vamsi K. Kota, Avirup Guha, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2024-209114

Published: 2024

Journal Articles

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Ibrahim Muhsen, Anjali S. Advani, Gregory W Roloff, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Michael R. Grunwald, Vamsi K. Kota, Jacob Boccucci, Matthew Ulrickson, Joshua Sasine, Ibrahim Aldoss, Tamer Othman, Sumithira Vasu, Ran Reshef, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Amelia Langston, Ryan D. Cassaday, Noam E. Kopmar, Stephanie B. Tsai, Timothy E O'Connor, Talal Hilal, Rawan Faramand, Jae H. Park, Yannis K. Valtis, Melhem M. Solh, Evandro Bezerra, Jessica T. Leonard, Simone E. Dekker, Navneet Majhail, Minoo Battiwalla, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Kaitlyn C Dykes, Aaron C. Logan, Muthu V. Kumaran, Wendy Stock, Marc Schwartz, Veronika Bachanova, Sean Tracy, Kristen M. O'Dwyer, Jozal Moore, Catherine J. Lee, Maria Silvina Odstrcil Bobillo, Noelle Frey, Matthew P Connor, Omer Jamy, Michael Daunov, Abdullah Ladha, George Yaghmour, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Vinod Pullarkat, Akil Merchant, Bijal D Shah, Lori Muffly, LaQuisa Hill

Blood (2024) 144 (Supplement 1): 523.

https://doi.org/10.1182/blood-2024-210682

Published: 2024

Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota

Blood (2024) 144 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2024-201831

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Incidence of Engraftment Syndrome with and without Budesonide Prophylaxis in Patient with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Stephanie Daniels, Lucy Gloe, Vamsi K. Kota, Alexandria Rakestraw, Amber Clemmons

Blood (2024) 144 (Supplement 1): 7116.

https://doi.org/10.1182/blood-2024-210832

Published: 2024

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

Rohan Vuppala, Charles Weeks, Mark Dalgetty, Danielle Bradshaw, Locke Johnson Bryan, Amany R. Keruakous, Anand Jillella, Vamsi K. Kota, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2024-211898

Published: 2024

Journal Articles

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Charles Weeks, Mahran Shoukier, Mark Dalgetty, Rohan Vuppala, Shreya Desai, Abigayle B Simon, Vamsi K. Kota, Locke Johnson Bryan, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2024-206129

Published: 2024

Journal Articles

Serum Ferritin Levels Prior to Mobilization and Collection May Not Influence Stem Cell Yield

Charles Weeks, Danielle Bradshaw, Sujith Abbagoni, Mohammad Mian, Sarah Jimenez, Courtney Corley, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2023-191204

Published: 2023

Journal Articles

The Overuse of C. Difficile T esting Among Autologous Transplant Patients with Melphalan Conditioning: A Single Center Experience

James Dickey, Meaghan Standridge, Shreya Desai, Isabela Pavkov, Stacy Bedore, Priyanshu Nain, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Anand Jillella, Jorge Cortes, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 7065.

https://doi.org/10.1182/blood-2023-191226

Published: 2023

Journal Articles

Are Pivotal CART Trials Representative of Population at Risk?

Anvay Shah, Vamsi K. Kota, Mycal Casey, Lorriane Odhiambo, Vishrut Shah, KM Islam, Anand Jillella, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan, Jorge Cortes

Blood (2023) 142 (Supplement 1): 5884.

https://doi.org/10.1182/blood-2023-191122

Published: 2023

Journal Articles

Real-World Outcomes for Primary CNS Lymphoma from a Single Academic Institution: The Augusta Experience

Michael Chahin, Sruthi Dontu, Amany R. Keruakous, Anand Jillella, Jorge Cortes, Vamsi K. Kota, Locke Johnson Bryan, Ayushi Chauhan

Blood (2023) 142 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2023-189357

Published: 2023

Journal Articles

Financial Trends of AML Patients over the Past Decade

Mark Dalgetty, Mahran Shoukier, Danielle Bradshaw, Faizan Boghani, Sruthi Athota, Anvay Shah, Meaghan Standridge, Michael Stokes, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5876.

https://doi.org/10.1182/blood-2023-191103

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Talha Badar, Ravi Narra, Alice Mims, Rory M. Shallis, Guilherme Sacchi De Camargo Correia, Cameron Hunter, Vamsi K. Kota, Shreya Desai, Anand Ashwin Patel, Adam S Duvall, Neil Palmisiano, Emily K Curran, Omer Zulfa, Anjali S. Advani, Ehab L. Atallah, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2023-188188

Published: 2023

Journal Articles

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Ibrahim Aldoss, Rawan Faramand, Noam E. Kopmar, Kaitlyn C Dykes, Nikeshan Jeyakumar, Simone E. Dekker, Vishal K Gupta, Mohamed Ahmed, Aaron C. Logan, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shabaz Malik, John Mathews, Paul Shaughnessy, Abdullah Ladha, George Yaghmour, Anjali S. Advani, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ryan D Cassaday, Bijal D. Shah, Katharine Miller, Lori S. Muffly, Ahmed Galal, Stephanie B. Tsai, Bhagirathbhai Dholaria

Blood (2023) 142 (Supplement 1): 671.

https://doi.org/10.1182/blood-2023-182566

Published: 2023

NARROW

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Incidence of Engraftment Syndrome with and without Budesonide Prophylaxis in Patient with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Serum Ferritin Levels Prior to Mobilization and Collection May Not Influence Stem Cell Yield

The Overuse of C. Difficile T esting Among Autologous Transplant Patients with Melphalan Conditioning: A Single Center Experience

Are Pivotal CART Trials Representative of Population at Risk?

Real-World Outcomes for Primary CNS Lymphoma from a Single Academic Institution: The Augusta Experience

Financial Trends of AML Patients over the Past Decade

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only